



Supplemental Fig. 1




Supplemental Figure 1. C57BL/6 mice were treated with either control rat-IgG2a, or anti-CD28 dAb on d 0, 2, 4 and 6 and spleens were harvested on d 8. (A) Phosphorylation status was determined by phosflow on Ly-6C⁻ Treg cells. (B) CD28^{-/-} or CD80/86^{-/-} mice were treated with rat-IgG2a or anti-ICOS every other d for 6 d and splenocytes were harvested on D8. Representative plots of CD4⁺Foxp3⁺ cells on d 8 after antibody treatment. (C) Expression of Ly-6C and Ki-67 on Treg cells after antibody treatment. (D) Percentage of Ki-67 expression on CD4⁺Foxp3⁻CD44⁺CD62L⁻ cells after antibody treatment.

Supplemental Fig. 2



Supplemental Figure 2. C57BL/6 mice were treated (i.p.) either anti-CTLA4, anti-PD1 or both or together with anti-CD28 dAb every other day for 6 d and splenocytes were harvested on d 8. Percentage of Ki-67 expression among: (A) Ly-6c⁻Treg, (B) CD4⁺Foxp3⁺CD44⁺, (C) CD8⁺CD44⁺CD62L⁺, and (D) CD8⁺CD44⁺CD62L⁻ subsets after antibody treatment. C57BL/6 mice were treated with mouse-IgG1, anti-BTLA, anti-CD48, anti-CD70, anti-TIGIT (agonistic), anti-TIM3 and anti-VISTA every other d for 6 d and immunophenotyping of splenocytes was performed on d 8. Percentage of Ki-67 expression on (E) Ly-6c⁻Treg, (F) CD4⁺Foxp3⁺CD44⁺, (G) CD8⁺CD44⁺CD62L⁺, and (H) CD8⁺CD44⁺CD62L⁻ subsets in treated mice.


Supplemental Fig. 3




Supplemental Figure 3. C57BL/6 mice were treated with (i.p.) either IL2:S4B6, IL2:JES6 alone in combination with anti-CD80/86 on d 0, 2, 4 and 6 and splenocytes were isolated on d 8 for immune phenotyping. Percentage of Ki-67 expression among (A) Ly-6C⁻ Treg, (B) CD4⁺Foxp3⁺CD44⁺ (C) CD8⁺CD44⁺CD62L⁺ and (D) CD8⁺CD44⁺CD62L⁻ subsets after antibody treatment. C57BL/6 mice were treated with mIgG2a, anti-IFNAR, anti-IFN γ , anti-IFN γ R, anti-TNF α , anti-IL-7 and anti-IL7Ra (250 μ g/dose) i.p every other d for 6 d and immunophenotyping of splenocytes was performed on d 8. Percentage of Ki-67 expression on (E) Ly-6C⁻Treg, (F) CD4⁺Foxp3⁺CD44⁺ (G) CD8⁺CD44⁺CD62L⁺ and (H) CD8⁺CD44⁺CD62L⁻ subsets in mAb treated or IL-33^{-/-} mice.

Supplemental Fig. 4


A




B



C



D



Supplemental Figure 4. C57BL/6 animals were injected (i.p.) with anti-GITR, anti-OX40, anti-4-1BB (250µg/dose) alone or together with anti-CD28 dAb (100µg/dose) on d 0, 2, 4 and 6 and splenocytes were harvested on d 8. Percentage of Ki-67 expression among (A) Ly-6C-Treg, (B) CD4⁺Foxp3⁺CD44⁺ (C) CD8⁺CD44⁺CD62L⁺ and (D) CD8⁺CD44⁺CD62L⁻ subsets after antibody treatments.